Blueberry Therapeutics, an Alderley Edge, UK-based developer of a topical antifungal, raised £3M in funding.
The round was led by the GM&C Life Sciences Fund, managed by Catapult Ventures, with participation from San Francisco-based InClin Investments, as well as a number of private investors.
The company will use the funds to advance its lead topical antifungal into human clinical trials.
Led by Dr. John Ridden, Chief Executive Officer, Dr Mike Davies, Chief Medical Officer and Dr. David Cook, Chief Scientific Officer, Blueberry Therapeutics is developing topical fungal infection therapies for onychomycosis (fungal nail infection) and associated tinea pedis (athlete’s foot).
FinSMEs
06/05/2016